Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-20
2011-12-13
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08076353
ABSTRACT:
In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5′-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.
REFERENCES:
patent: 3492304 (1970-01-01), Shavel et al.
patent: 4014890 (1977-03-01), Welch, Jr. et al.
patent: 4720484 (1988-01-01), Vincent et al.
patent: 4754038 (1988-06-01), Abou-Gharbia
patent: 5039801 (1991-08-01), Brossi et al.
patent: 5120543 (1992-06-01), Hagin et al.
patent: 5206377 (1993-04-01), McAfee
patent: 5314908 (1994-05-01), McAfee
patent: 5382569 (1995-01-01), Cody et al.
patent: 5403851 (1995-04-01), D'Orlando et al.
patent: 5580878 (1996-12-01), D'Orlando et al.
patent: 5622960 (1997-04-01), Pommier et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5760051 (1998-06-01), Audia et al.
patent: 6043252 (2000-03-01), Bombrun
patent: 6048868 (2000-04-01), Fourtillan et al.
patent: 6069150 (2000-05-01), Spinelli et al.
patent: 6235718 (2001-05-01), Balasubramanium et al.
patent: 6306870 (2001-10-01), Bombrun
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6350757 (2002-02-01), Goldstein et al.
patent: 6376529 (2002-04-01), Tang et al.
patent: 6552017 (2003-04-01), Robichaud et al.
patent: 6635638 (2003-10-01), Sui et al.
patent: 6706750 (2004-03-01), Bentley et al.
patent: 6890933 (2005-05-01), Feng et al.
patent: 7601840 (2009-10-01), Moon et al.
patent: 7767689 (2010-08-01), Moon et al.
patent: 2002/0016298 (2002-02-01), Hay et al.
patent: 2002/0091125 (2002-07-01), Hay et al.
patent: 2002/0128206 (2002-09-01), Hay et al.
patent: 2002/0173503 (2002-11-01), Robichaud et al.
patent: 2003/0023087 (2003-01-01), Garvey et al.
patent: 2003/0040527 (2003-02-01), Yeh et al.
patent: 2003/0130171 (2003-07-01), Schoenhard
patent: 2003/0220377 (2003-11-01), Chesworth
patent: 2004/0023947 (2004-02-01), Martin et al.
patent: 2004/0058877 (2004-03-01), Hay et al.
patent: 2004/0116458 (2004-06-01), Sawyer et al.
patent: 2004/0127482 (2004-07-01), Robichaud et al.
patent: 2004/0157834 (2004-08-01), Hay et al.
patent: 2004/0186094 (2004-09-01), Robichaud et al.
patent: 2004/0209864 (2004-10-01), Robichaud et al.
patent: 2004/0214223 (2004-10-01), Cao et al.
patent: 2004/0214848 (2004-10-01), Schoenhard
patent: 2004/0229864 (2004-11-01), Bourrain et al.
patent: 2005/0004156 (2005-01-01), Feng et al.
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: 2005/0054634 (2005-03-01), Busch et al.
patent: 2005/0143371 (2005-06-01), Meyers et al.
patent: 2005/0267018 (2005-12-01), Blatt et al.
patent: 2005/0272759 (2005-12-01), Moon et al.
patent: 2005/0282849 (2005-12-01), Moon et al.
patent: 2007/0254878 (2007-11-01), Cao et al.
patent: 2008/0103213 (2008-05-01), Kurzrock et al.
patent: 2008/0293766 (2008-11-01), Diamond et al.
patent: 2009/0017021 (2009-01-01), Davis et al.
patent: 2010/0125065 (2010-05-01), Moon et al.
patent: 2010/0158858 (2010-06-01), Cao et al.
patent: 2010/0179132 (2010-07-01), Moon et al.
patent: 2099060 (1993-12-01), None
patent: 0008249 (1981-08-01), None
patent: 0357122 (1990-03-01), None
patent: 0406734 (1991-01-01), None
patent: 0468789 (1992-01-01), None
patent: 0491943 (1992-07-01), None
patent: 0549916 (1993-07-01), None
patent: 0549916 (1993-08-01), None
patent: 0719837 (1995-12-01), None
patent: 0300541 (1996-03-01), None
patent: 1512397 (2005-03-01), None
patent: 1383765 (2006-12-01), None
patent: 2432025 (1980-02-01), None
patent: 2662940 (1991-12-01), None
patent: 3-287586 (1991-12-01), None
patent: 4-275221 (1992-09-01), None
patent: 94/10175 (1994-05-01), None
patent: 94/11378 (1994-05-01), None
patent: 9410175 (1994-05-01), None
patent: 96/26207 (1996-08-01), None
patent: 9632003 (1996-10-01), None
patent: 9737658 (1997-10-01), None
patent: 97/43287 (1997-11-01), None
patent: 9906390 (1999-02-01), None
patent: 0039314 (2000-07-01), None
patent: 01/21589 (2001-03-01), None
patent: 0121584 (2001-03-01), None
patent: 0147887 (2001-07-01), None
patent: 01/87038 (2001-11-01), None
patent: 01/87038 (2001-11-01), None
patent: 02/051805 (2002-07-01), None
patent: 02/088123 (2002-11-01), None
patent: 03033496 (2003-04-01), None
patent: 03051841 (2003-06-01), None
patent: 03087815 (2003-10-01), None
patent: 03099821 (2003-12-01), None
patent: 03103656 (2003-12-01), None
patent: 2004/035047 (2004-04-01), None
patent: 2004069831 (2004-08-01), None
patent: 2004096766 (2004-11-01), None
patent: 2004110999 (2004-12-01), None
patent: 2004113336 (2004-12-01), None
patent: 2005000246 (2005-01-01), None
patent: 2005005386 (2005-01-01), None
patent: 2005007672 (2005-01-01), None
patent: 2005/014543 (2005-02-01), None
patent: 2005009370 (2005-02-01), None
patent: 2005070930 (2005-03-01), None
patent: 2005037791 (2005-04-01), None
patent: 2005089764 (2005-09-01), None
patent: 2005097162 (2005-10-01), None
patent: 2005113003 (2005-12-01), None
patent: 2006015035 (2006-02-01), None
patent: 2006058088 (2006-06-01), None
patent: 2006/113703 (2006-10-01), None
patent: WO 2008/127714 (2008-10-01), None
patent: WO 2008/127715 (2008-10-01), None
patent: WO 2010/138644 (2010-12-01), None
patent: WO 2010/138652 (2010-12-01), None
patent: WO 2010/138659 (2010-12-01), None
patent: WO 2010/138685 (2010-12-01), None
patent: WO 2010/138695 (2010-12-01), None
patent: WO 2010/138706 (2010-12-01), None
patent: WO 2010/138758 (2010-12-01), None
Calabresi P and Chabner BA, “Section IX Chemotherapy of Neoplastic Diseases—Introduction,” Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed., 2001, Hardman JG, Limbird LE, and Gilman AG, Eds, McGraw-Hill, New York 2001, 1381-1388 (pp. 1381, 1383-1385, and 1388 provided).
Kuldo JM, Ogawara KI, Werner N, Asgeirsdóttir SA, Kamps JA, Kok RJ, and Molema G, “Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases,” Current Vascular Pharmacology, Jan. 2005, 3(1), 11-39.
Roodink I and Leenders WP, “Targeted therapies of cancer: angiogenesis inhibition seems not enough,” Cancer Letters, Dec. 2010, 299(1), 1-10.
Abou-Gharbia et al., “Antipsychotic Activity of Substituted Gamma-Carbolines,” J. Med. Chem., 30:1818-1823 (1987).
Akiri et al., “Regulation of Vascular Endothelial Growth Factor (VEGF) Expression is Mediated by Internal Initiation of Translation and Alternative Initiation of Transcription,” Oncogene, 17:227-236 (1998).
Asano et al., “Wide Spectrum of Antitumor Activity of a Neutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor,” Jpn. J. Cancer Res., 90:93-100 (1999).
Bergsland et al., “A Randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Human Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus 5-Flurouracil/Leucovorin (FU/LV) to FU/LV Alone in Patients with Metastatic Colorectal Cancer,” American Society of Clinical Oncology 36th Annual Meeting, May 2000, New Orleans, LA, USA, Abstract No. 939.
Borgström et al., “Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors In Vivo,” Prostate, 35:1-10 (1998).
Bornes et al., “Control of the Vascular Endothelial Growth Factor Internal Ribosome Entry Side (IRES) Activity and Translation Initiation by Alternatively Spliced Coding Sequences,” J. Biol. Chem., 279(18):18717-18726 (2004).
Boyer, “Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships,” Current Topics in Medicinal Chemistry, 2:973-1000 (2002).
Brekken et al., “Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDF/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice,” Cancer Res., 60:5117-5124 (2000).
Cao et al., “Synthesis and in vitro Cytotoxic Evaluation of 1,3-Bisubstituted and 1,3,9-Trisubsti
Cao Liangxian
Davis Thomas W.
Romfo Charles M.
Trotta Christopher R.
Hui San-Ming
Jones Day
PTC Therapeutics, Inc.
Zarek Paul
LandOfFree
Inhibition of VEGF translation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of VEGF translation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of VEGF translation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4309902